This study is being done to answer the following question: What are the effects (good or bad) of adding a study drug (duvelisib or CC-486 (azacitidine)) to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for T-cell lymphoma. The usual approach is defined as care most people get for peripheral T-cell lymphoma.
COM_RESEARCHSTUDIES_DETAIL_HEADER_BASIC_CONTACT_4
United States (Nationwide)
Anne Beaven
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Lymphoma)
22-1274